MyFinsight
Home
Blog
About
Proceeds from revolving
credit facility
$3,600,000
Proceeds from issuance of
common stock
$311,024
(-94.74%↓ Y/Y)
Net cash flows from
financing activities
$3,468,427
(-57.44%↓ Y/Y)
Canceled cashflow
$442,597
Net change in cash
and cash...
-$5,302,150
(-27.94%↓ Y/Y)
Canceled cashflow
$3,468,427
Stock compensation
expense
$2,143,234
(-24.32%↓ Y/Y)
Amortization of deferred loan
costs
$295,290
Accrued interest
-$172,344
Other noncurrent
assets
-$38,867
(-155.22%↓ Y/Y)
Depreciation and
amortization
$28,104
(2.46%↑ Y/Y)
Other current assets
-$24,266
(78.02%↑ Y/Y)
Payment of placement
agent fees and...
$227,008
Payment of revolving
credit facility debt...
$202,450
Principal payments of
finance lease
$11,050
Cash dividend
payment of preferred...
$2,089
(-50.00%↓ Y/Y)
Net cash flows from
operating activities
-$8,633,599
(21.42%↑ Y/Y)
Canceled cashflow
$2,702,105
Net cash flows from
investing activities
-$136,978
(89.52%↑ Y/Y)
Net loss
-$9,223,298
(43.02%↑ Y/Y)
Accounts payable and
accrued expenses
-$2,112,406
(-191.75%↓ Y/Y)
Purchase of property and
equipment
$136,978
(183.99%↑ Y/Y)
Back
Back
Cash Flow
TuHURA Biosciences, Inc. NV (HURA)
TuHURA Biosciences, Inc. NV (HURA)
source: myfinsight.com